News | May 25, 2021
Astrazeneca Pharma India Q4FY21 net profit up at Rs 27.27 Cr
The company has reported total income of Rs.826.40 crores for FY 2020-21
The company has reported total income of Rs.826.40 crores for FY 2020-21
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
The company reported total income of Rs.455.28 crores during the 12 months period ended March 31, 2021
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
The company has posted net loss of Rs. 99.54 crores for the period ended March 31, 2020
The agreement will help ensure wider reach and access to patients in India
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
The companyreported total income of Rs.2915.67 crores during the 12 months period ended March 31, 2021
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
Subscribe To Our Newsletter & Stay Updated
